N/A N=205 Depression Attention for Women Now (The DAWN Study)
Depressive Disorder
Primary: Depression Treatment Outcome — 0.96; 1.33 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=598 Efficacy Study of Vortioxetine on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder
Major Depressive Disorder
Primary: Change From Baseline to Week 8 in DSST (Number of Correct Symbols) and RAVLT (Acquisition and Delayed Recall) Using the Composite Z-score Defined as the Weighted Sum of…
Phase 2 N=97 Assessing Symptomatic Clinical Episodes in Depression
Major Depressive Disorder
Primary: MADRS Score - Overall Change From Baseline — 13.7; 8.8 score on a scale — p=<.001
Phase 2 N=204 Study in Major Depressive Disorder With NMRA-335140 (BTRX-335140) vs Placebo
Major Depressive Disorder
Primary: Change From Baseline in Hamilton Depression Rating Scale (HAMD-17) Total Score at Weeks 8 — -9.0; -7.4 Scores on a scale — p=0.121
Phase 3 N=48 Major Depressive Disorder With Mixed Features - Extension
Major Depressive Disorder
Primary: Percentage of Subjects With Treatment Emergent Adverse Events (TEAEs) — 66.7 percentage of subjects
N/A N=9 European Deep Brain Stimulation (DBS) Depression Study
Depressive Disorder, Major
Primary: Mean Percent Change From Baseline in MADRS Score — -7.7; -7.4; -8.8; -6.2 percentage change from baseline
Phase 3 N=337 A Study in the Treatment of Children and Adolescents With Major Depressive Disorder
Major Depressive Disorder
Primary: Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Total Score at Week 10 Endpoint — -24.3; -23.7; -24.3 units on a scale — p=0.999
Phase 3 N=463 A Study in the Treatment of Children and Adolescents With Major Depressive Disorder
Major Depressive Disorder
Primary: Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Total Score at Week 10 Endpoint — -23.9; -21.6 units on a scale — p=0.193
Phase 2 N=273 A Phase 2 Trial of OPC-64005 for Major Depressive Disorder
Major Depressive Disorder
Primary: Mean Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at Week 6 of the Double-blind Treatment Period — -1.9; -1.6; -2.1; -3.9 Units…
Phase 2 N=504 MDD POC Study GSK372475 Subjects Depressive Disease
Depressive Disorder
Primary: Mean Change From Randomization at the End of the Treatment Phase in the MADRS Total Score — -16.9; -19.0; -20.5 Score on scale — p=0.485
Phase 3 N=211 Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose
Major Depressive Disorder With Mixed Features
Primary: Mean Change From Baseline to the 6-week Study Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Scores — -20.5; -13.0 units on a scale — p=<0.0001
Phase 3 N=569 A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD)
Depressive Disorder, Major
Primary: Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 8/Withdrawal — -13.9; -14.4; -12.9 Scores on a scale — p=0.853
Phase 3 N=513 A Study of Fluoxetine in Major Depressive Disorder (MDD) Short-Term Dosing
Major Depressive Disorder
Primary: Mean Change From Baseline to 6-Week Endpoint on the 21-Item Hamilton Depression Rating Scale (HAMD21) Total Score — -6.18; -6.25; -6.91 units on a scale — p=0.264
Phase 4 N=85 Advancing Personalized Antidepressant Treatment Using PET/MRI
Depression
Primary: Change From Baseline in Hamilton Depression Rating Scale at 8 Weeks — 11.81; 9.41 score on a scale
Phase 4 N=480 Study Comparing Discontinuation Symptoms Of DVS SR In Subjects With Major Depressive Disorder (MDD)
Major Depressive Disorder
Primary: Total Discontinuation - Emergent Signs and Symptoms (DESS) Score Over the First 2 Weeks of the Double-blind Phase — 4.1; 4.8; 5.3 scores on a scale
Phase 3 N=327 A Trial of AXS-05 in Patients With Major Depressive Disorder
Depression · Major Depressive Disorder
Primary: Change in MADRS Total Score From Baseline to Week 6 — 15.91; 12.04 score on a scale — p=0.002
N/A N=386 Trial to Evaluate the Effectiveness of a Digital Therapeutics in Adults Diagnosed With Major Depressive Disorder
Major Depressive Disorder
Primary: Change From Baseline to Week 6 in the MADRS Total Score — -9.03; -7.25 score on a scale — p=0.0568
Phase 3 N=1,149 A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder
Major Depressive Disorder
Primary: Phase C: Time-to-Relapse by Any Criteria as Defined in Blinded Addendum — 63.0; 63.0 days — p=0.5100
Phase 2 N=769 Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder
Major Depressive Disorder
Primary: Change From the End of Phase A (Week 8 Visit) to the End of Phase B (Week 14 Visit) in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score. — -8.20; -7.02…
N/A N=851 Study Comparing Remission Rates, in Patients With Major Depressive Disorder (MDD)
Major Depressive Disorder
Primary: Percentage of Participants With Remission Based on Hamilton Depression Scale (HAM-D) — 54.4 Percentage of participants
Phase 2 N=360 A Study to Evaluate the Efficacy and Safety of MIN-117 in Adult Patients With Major Depressive Disorder
Major Depressive Disorder
Primary: Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -12; -12; -12 score on a scale
N/A N=26 Transcranial Direct Current Stimulation Therapy for Major Depression
Major Depressive Disorder
Primary: Clinical Response — 22 Participants
Phase 2 N=296 Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care for Depression
Depression
Primary: Hamilton Rating Scale for Depression — 11.06; 12.52 units on a scale
N/A N=48 Standardized Versus Tailored Implementation of Measurement Based Care for Depression
Depression
Primary: Patient Health Questionnaire — 18.04; 16.77; 12.15; 13.09 score on a scale
Phase 4 N=30 Duloxetine Treatment in Elderly With Dysthymia
Depression · Dysthymic Disorder
Primary: Change in Hamilton Rating Scale for Depression (HAM-D, 24-item) From 0 Weeks to 12 Weeks. — 8 units on a scale — p=<0.001
N/A N=11 Maintenance Transcranial Magnetic Stimulation in Major Depressive Disorder
MDD
Primary: Depression Severity Changes Scored From Patient Health Questionnaire (PHQ9) — 5; 6.71; 8.14; 9.14 score on a scale
Phase 4 N=68 Cost- Effectiveness and Quality of Life Assessment in Major Depression Disorder
Depression
Primary: Number of Participants With Response to Treatment — 58 Participants
N/A N=12,909 Universal vs. Targeted School Screening for Adolescent Major Depressive Disorder
Major Depressive Disorder · Major Depressive Episode
Primary: Major Depressive Disorder (MDD) Composite: Positive Patient Health Questionnaire-9 (PHQ-9; Universal Arm) or MDD Concern Prompting Student Assistance Program (SAP)…
N/A N=255 Cranial Electrotherapy Stimulation for the Treatment of Major Depressive Disorder in Adults
Major Depressive Disorder
Primary: Change in the Beck Depression Inventory Second Edition (BDI-II) at Week Two Compared to Baseline. — 16.65; 14.36 units on a scale — p=0.056
Phase 3 N=543 A Study to Evaluate the Efficacy of Sage-217 in the Treatment of Adult Participants With Major Depressive Disorder (MDD)
Depressive Disorder, Major
Primary: Change From Baseline in the 17-item HAM-D Total Score at Day 15 — -12.3; -14.1 score on a scale — p=0.0141